Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1621-1630 Newer>

The Motley Fool December 17, 2004 Brian Gorman	Sepracor's Dream Drug? Investors should be awake to Lunesta's potential pitfalls.
The Motley Fool December 17, 2004 W.D. Crotty	Painful Pain Drugs Pfizer joins Merck in the COX-2 inhibitor penalty box. Pfizer's stock, has drifted down since the Vioxx news.
Bio-IT World December 15, 2004 Nancy Weil	Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic.
Bio-IT World December 15, 2004	Sourcebook: Laboratory Information Management Systems One result of the past year's mad merger activity in the pharma industry is that companies are re-evaluating their laboratory systems, looking to standardize on one Laboratory Information Management System that supports global business practices.
Bio-IT World December 15, 2004 Kevin Davies	Into the Valley of Innovation An interview with president and CEO Curt Carlson of research hothouse SRI International on new technology and accelerating drug development.
Bio-IT World December 15, 2004 Zachary Zimmerman	Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies.
Bio-IT World December 15, 2004 Kevin Davies	First Trilogy Machine Installed at Mount Sinai A landmark installation for U.S. Genomics' Single Molecule Analyzer.
Bio-IT World December 15, 2004 Kevin Davies	Patients Before Profits? After the Vioxx disaster, Pharma needs to reassure patients that they come first.
BusinessWeek December 27, 2004 Carol Matlack	Growing Pains At Sanofi The pipeline looks good at the world's No. 3 drugmaker -- but investors are waiting for cost cuts.
BusinessWeek December 27, 2004 Kerry Capell	The End Of Obesity As We Know It Sanofi-Aventis' Acomplia takes aim at two of the great maladies of the century. But approval isn't a slam dunk.
<Older 1621-1630 Newer> Return to current articles.